🇺🇸 FDA
Pipeline program

FULVESTRANT, camizestrant, camizestrant

D8530C00002

Phase 2 small_molecule active

Quick answer

FULVESTRANT, camizestrant, camizestrant for Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials